Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 8, 2003, Pages 959-968

  Lörincz, Attila T ^a   Richart, Ralph M ^b  

^a Digene Corporation   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; DIAGNOSTIC AGENT;

ADOLESCENT; ADULT; AGED; CANCER SCREENING; CONFERENCE PAPER; CONFIDENCE INTERVAL; COST CONTROL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA DETERMINATION; FEMALE; HEALTH PROGRAM; HUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; PUBLICATION; RELIABILITY; RISK ASSESSMENT; SAFETY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS; CYTODIAGNOSIS; DIAGNOSTIC PROCEDURE; DNA PROBE; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; METHODOLOGY; PAPILLOMA VIRUS; PATHOLOGY; REVIEW; UTERINE CERVIX; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

CERVIX UTERI; CYTODIAGNOSIS; DNA PROBES, HPV; FEMALE; HUMANS; MASS SCREENING; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0041673350     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265.
2. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992;79:328-337.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;87:796-802.
4. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
5. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92:464-474.
6. Thomas DB, Qin Q, Kuypers J, et al. Human papillomaviruses and cervical cancer in Bangkok, II: risk factors for in situ and invasive squamous cell cervical carcinomas. Am J Epidemiol. 2001;153:732-739.
7. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810-819.
8. Bastian L, Datta S, Hasselblad V, Hickey J, Myers E, Nanda K. Evaluation of cervical cytology, 5. 1999. Rockville, Md: Agency for Health Care Policy and Research (AHCPR). Evidence report/technology assessment prepared by Duke University under contract 290-97-0014. AHCPR publication 99-E010. Available at: http://hstat.nlm. nih.gov/hq/Hquest/db/local.epc.er.cyt/screen/DocTitle/s/48139. Accessed February 25, 2003.
9. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;141:680-689.
10. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA. 2002;288:1749-1757.
11. Solomon D, Schiffman M, Tarone B, for the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance (ASCUS): baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
12. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst. 1993;85:958-964.
13. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180:1415-1423.
14. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst. 2002;94:102-107.
15. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, for the 2001 ASCCP-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-2129.
16. Lorincz A, Anthony J. Advances in HPV detection by Hybrid Capture®. Pap Report. 2001;12:145-154.
17. Jacobs MV, Snijders PJF, van den Brule AJC, Helmerhorst TJM, Meijer CJLM, Walboomers JMM. A general primer GP5+/GP6+-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791-795.
18. Manos MM, Ting Y, Wright DK, Lewis AJ, Broker TR, Wolinsky SM. Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. In: Furth M, Greaves M, eds. Molecular Diagnostics of Human Cancer. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989:209-214.
19. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol. 2002;68:417-423.
20. Kjaer SK, van den Brule AJC, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002;325:572-578.
21. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439-444.
22. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
23. Hall S, Lorincz A, Shah F, et al. Human papillomavirus DNA detection in cervical specimens by Hybrid Capture: correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix. Gynecol Oncol. 1996; 62:353-359.
24. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
25. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer. 1999;81:554-558.
26. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev. 2000;9:945-951.
27. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA. 2000;283:81-86.
28. Clavel C, Masure M, Bory J-P, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;89:1616-1623.
29. Schneider A, Hoyer H, Lotz B, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89:529-534.
30. Salmeron J, Lazcano EC, Lorincz A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control. In press.
31. Petry K-U, Menton S, Menton M, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8468 patients. Br J Cancer. 2003;88:1570-1577.
32. Liaw K-L, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intra-epithelial lesions. J Natl Cancer Inst. 1999;91:954-960.
33. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus infected women. J Natl Cancer Inst. 2002;94:1406-1414.
34. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002;360:228-229.
35. Bory J-P, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the Hybrid Capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer. 2002;102:519-525.
36. Jain S, Tseng C-J, Horng S-G, Soong Y-K, Pao CC. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecol Oncol. 2001;82:177-180.
37. Lin C-T, Tseng C-J, Lai C-H, et al. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am J Obstet Gynecol. 2001;184:940-945.
38. Paraskevaidis E, Koliopoulos G, Alamanos Y, Malamou-Mitsi V, Lolis ED, Kitchener HC. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 2001;98:833-836.
39. Jacobs MV, Zielinski D, Meijer CJLM, et al. A simplified and reliable HPV testing of archival Papanicolaou-stained cervical smears: application to cervical smears from cancer patients starting with cytologically normal smears. Br J Cancer. 2000;82:1421-1426.
40. Zielinski GD, Snijders PJF, Rozendaal L, et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer. 2001;85:398-404.
41. Allen KA, Zaleski S, Cohen MB. Review of negative Papanicolaou tests: is the retrospective 5-year review necessary? Am J Clin Pathol. 1994;101:19-21.
42. Wallin K-L, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633-1638.
43. Nobbenhuis MAE, Warboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20-25.
44. Rozendaal L, Walboomers JMM, van der Linden JC, et al. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996;68:766-769.
45. Hutchinson ML, Cassin CM, Ball HG III. The efficacy of an automated preparation device for cervical cytology. Am J Clin Pathol. 1991;96:300-305.
46. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:2372-2381.
47. Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less developed countries. J Natl Cancer Inst. 2002;94:1469-1483.
48. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107-3115.
49. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.